Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
OXTELLAR XR vs ALFENTANIL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Oxtellar XR (oxcarbazepine) is a prodrug that is converted to its active metabolite, MHD (10,11-dihydro-10-hydroxy-carbazepine). The exact mechanism of action is unknown, but it is thought to stabilize neuronal membranes by blocking voltage-gated sodium channels, thereby inhibiting repetitive neuronal firing and reducing the propagation of synaptic impulses.
Alfentanil is a potent, short-acting synthetic opioid analgesic that primarily acts as a mu-opioid receptor agonist. It binds to mu-opioid receptors in the central nervous system, leading to G-protein coupled activation of inwardly rectifying potassium channels and inhibition of voltage-gated calcium channels, resulting in hyperpolarization and reduced neurotransmitter release. This produces analgesia, sedation, and respiratory depression.
FDA-approved as monotherapy or adjunctive therapy for partial-onset seizures in adults and children aged 4 years and older,Off-label: bipolar disorder, trigeminal neuralgia, diabetic neuropathy
Analgesic adjunct during general anesthesia,Induction of anesthesia,Maintenance of anesthesia for short surgical procedures,Off-label: Procedural sedation in monitored settings
Oxcarbazepine extended-release (OXTELLAR XR) adult dosing: 600 mg orally twice daily; initial dose 300 mg twice daily, titrate by 300 mg/day increments weekly; maximum 2400 mg/day.
Initial IV bolus of 5-20 mcg/kg; maintenance infusion of 0.5-1.5 mcg/kg/min; incremental boluses of 5-10 mcg/kg as needed. Induction of anesthesia: 50-100 mcg/kg IV.
Terminal half-life approximately 20-30 hours in adults; after multiple doses, effective half-life is about 24 hours, allowing once-daily dosing. Steady state reached in 4-5 days.
Terminal elimination half-life: 90–111 minutes (1.5–1.85 hours). Clinically, context-sensitive half-time is short (~40 min after 3-hour infusion) due to rapid redistribution and metabolism.
Oxcarbazepine is extensively metabolized by cytosolic enzymes to the active metabolite MHD (10,11-dihydro-10-hydroxy-carbazepine). MHD undergoes further glucuronidation and is excreted renally. Minor metabolism via CYP450 enzymes (CYP3A4/5) accounts for a small fraction.
Alfentanil is primarily metabolized by hepatic cytochrome P450 enzymes, mainly CYP3A4, through oxidative N-dealkylation and O-demethylation to inactive metabolites.
Primarily renal (70-80% as unchanged drug and metabolites) and fecal (20-30% via biliary excretion).
Primarily hepatic metabolism via CYP3A4; <1% excreted unchanged in urine; metabolites (mainly noralfentanil) excreted renally. Biliary/fecal excretion of metabolites accounts for ~30%.
Approximately 40% bound to serum proteins, mainly albumin.
~92% bound primarily to alpha-1-acid glycoprotein (AAG) and albumin.
0.7-0.8 L/kg, indicating distribution into total body water and some tissue binding.
Vd: 0.4–1.0 L/kg (mean ~0.75 L/kg). Moderate Vd reflecting rapid distribution to tissues, especially brain and muscle.
Extended-release: 80-90% relative to immediate-release. No significant food effect.
IV: 100%. IM: ~90%. Epidural: ~30–50% due to local uptake and redistribution. No significant oral bioavailability.
For creatinine clearance <30 m L/min: start at 150 mg twice daily (300 mg/day) and titrate slowly; patients with ESRD on dialysis: not recommended due to lack of data.
GFR 10-50 m L/min: administer with caution, consider dose reduction of 25-50%; GFR <10 m L/min: reduce dose by 50% and extend dosing interval.
Mild to moderate hepatic impairment (Child-Pugh A or B): no dose adjustment required. Severe hepatic impairment (Child-Pugh C): not studied; use with caution.
Child-Pugh class A: no adjustment needed; Child-Pugh class B: reduce dose by 50%; Child-Pugh class C: reduce dose by 75%.
For patients 6 years and older: oxcarbazepine XR (OXTELLAR XR) is not approved; use immediate-release oxcarbazepine based on weight: 8-10 mg/kg/day initially, titrated over 2 weeks to target 300-600 mg/day for 20-29 kg, 600-900 mg/day for 29.1-39 kg, 900-1200 mg/day for >39 kg. Not recommended under 6 years.
Initial IV bolus of 5-20 mcg/kg; maintenance infusion of 0.5-2 mcg/kg/min. For neonates, reduce dose by 30-50% due to immature clearance.
Elderly patients may have reduced clearance; start at 150 mg twice daily (300 mg/day) and titrate slowly. Monitor for hyponatremia, especially in those on diuretics or with low baseline sodium.
Reduce initial IV bolus by 30-50% to 3-10 mcg/kg; titrate carefully; monitor for prolonged sedation and respiratory depression.
None
Risk of respiratory depression: Alfentanil can cause severe, life-threatening, or fatal respiratory depression. Monitor for respiratory depression, especially during initiation or following dose increases. Accidental ingestion of even one dose can be fatal. Concomitant use with central nervous system depressants (e.g., benzodiazepines, alcohol) may increase risk. Alfentanil is an opioid agonist and a Schedule II controlled substance with high potential for abuse and addiction.
Hyponatremia (sodium <125 mmol/L) can occur, especially in elderly or patients on other hyponatremic drugs; monitor sodium levels,Serious dermatological reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis) - discontinue if rash develops,Suicidal behavior and ideation: monitor for worsening depression or suicidal thoughts,Dizziness, somnolence, ataxia: caution with activities requiring alertness,Multi-organ hypersensitivity reactions: discontinue if suspected,Withdrawal seizures: do not discontinue abruptly,Hematologic effects: rare agranulocytosis, aplastic anemia; monitor CBC if symptoms occur
Respiratory depression: Potentially fatal; monitor oxygenation and ventilation.,Abuse potential: Schedule II controlled substance; risk of addiction, abuse, and diversion.,Concomitant use with CNS depressants: Increases risk of profound sedation, respiratory depression, coma, and death; limit use or monitor closely.,Geriatric and cachectic patients: Increased sensitivity; reduce initial dose.,Hepatic impairment: Alfentanil clearance is reduced in patients with cirrhosis; consider dose adjustment.,Bradycardia and hypotension: Use with caution in patients with hypovolemia or reduced cardiac reserve.,Serotonin syndrome: Risk with concurrent serotonergic drugs (e.g., MAOIs, SSRIs, triptans); monitor for symptoms.,Withdrawal: Prolonged use may lead to physical dependence; taper dose gradually.
Known hypersensitivity to oxcarbazepine or any component of the formulation,Concurrent use with monoamine oxidase inhibitors (MAOIs) due to risk of hypertensive crisis
Hypersensitivity to alfentanil, fentanyl, or any opioid,Significant respiratory depression (e.g., acute asthma, COPD in acute exacerbation),Acute or severe bronchial asthma,Suspected or known paralytic ileus,MAO inhibitor use within 14 days (serotonin syndrome risk),Myasthenia gravis (relative contraindication due to risk of respiratory muscle weakness),Morbid obesity with sleep apnea (relative contraindication; increased risk of respiratory depression)
Take with or without food consistently. Avoid grapefruit juice (may affect drug metabolism). No specific food restrictions but maintain consistent dietary habits to avoid fluctuations in absorption.
No significant food interactions known. Avoid grapefruit and grapefruit juice as they may inhibit CYP3A4 metabolism, potentially prolonging effects.
Oxcarbazepine, the active moiety in Oxtellar XR, is associated with an increased risk of major congenital malformations, particularly neural tube defects, craniofacial defects, and cardiovascular anomalies, when used during the first trimester. In the second and third trimesters, use may be associated with adverse neurodevelopmental outcomes. The risk is dose-dependent and may be potentiated by concomitant antiepileptic drugs.
Alfentanil is an opioid analgesic; limited human data. No clear evidence of major malformations, but third trimester use may cause neonatal opioid withdrawal syndrome (NOWS). Avoid prolonged use or high doses near term; use during labor may cause respiratory depression in neonate.
Oxcarbazepine and its active metabolite (MHD) are excreted into breast milk. The infant's plasma MHD concentration is approximately 10-30% of the maternal level, with M/P ratio for MHD estimated at 0.5-1.0. While generally considered compatible with breastfeeding, monitor the infant for drowsiness, poor feeding, and rash.
Alfentanil is excreted into breast milk in very low concentrations; estimated relative infant dose is low (<2% of maternal weight-adjusted dose). M/P ratio not determined in humans. Compatible with breastfeeding with caution; monitor infant for drowsiness, feeding difficulties.
Due to increased clearance and volume of distribution during pregnancy, especially in the third trimester, dosage increments may be necessary to maintain therapeutic levels. Monitoring MHD trough concentrations and adjusting dose to achieve target levels is recommended. Postpartum, dose reduction may be required.
Pregnancy can alter alfentanil pharmacokinetics: increased volume of distribution, decreased plasma clearance, prolonged elimination half-life. Dose reduction may be needed for prolonged use; titrate to effect. During labor, use smallest effective dose.
Oxtellar XR (oxcarbazepine extended-release) is a voltage-gated sodium channel blocker used as adjunctive therapy for partial-onset seizures. Titrate slowly to minimize CNS side effects; start at 600 mg/day and increase weekly by 300 mg/day to target 1200-2400 mg/day. Monitor serum sodium levels frequently, especially in elderly or patients on other hyponatremic drugs. Dose adjustments needed in renal impairment (Cr Cl <30 m L/min: start at 300 mg/day). A 20% increase in dose may be required when switching from immediate-release oxcarbazepine. CYP3A4/5 inducer; may reduce efficacy of hormonal contraceptives.
Alfentanil is a potent, short-acting synthetic opioid (4-5 times more potent than fentanyl) with rapid onset (1-2 min) and brief duration (5-10 min). Primarily used for induction and maintenance of anesthesia, especially in short procedures. Requires careful monitoring of respiratory depression and chest wall rigidity, particularly during rapid IV administration. Hepatic metabolism (CYP3A4) affected by liver disease; reduce dose. Decrease dose in elderly and hypovolemic patients. Not recommended for chronic pain due to short half-life.
Take once daily with or without food; swallow tablet whole, do not crush or chew.,Report symptoms of hyponatremia: nausea, headache, confusion, lethargy, weakness.,May cause dizziness, somnolence, or ataxia; avoid driving until effects known.,Serious skin reactions (SJS/TEN) possible; seek immediate care for rash or blisters.,Hormonal contraceptives may be less effective; use additional non-hormonal method.,Do not stop abruptly; taper to avoid withdrawal seizures.,Avoid alcohol; may worsen CNS depression.
This medication causes drowsiness and dizziness; avoid driving or operating machinery for at least 24 hours after administration.,Report any difficulty breathing, chest tightness, or feeling faint immediately.,Alfentanil is used only in hospital settings under direct supervision of healthcare professionals.,Inform your doctor if you have a history of liver disease, lung disease, or drug/alcohol abuse.,Do not consume alcohol or other sedatives while under the effects of alfentanil.
No interactions on record
"Propantheline, an anticholinergic agent, can competitively antagonize muscarinic acetylcholine receptors, potentially reducing gastrointestinal motility and secretion. Alfentanil, a mu-opioid receptor agonist, also decreases gastrointestinal motility through central and peripheral opioid receptors. Concomitant use may synergistically inhibit peristalsis, leading to severe constipation, paralytic ileus, or delayed gastric emptying, which can increase the risk of aspiration and complicate anesthesia recovery."
"Alfentanil, a potent opioid analgesic, can cause significant hypotension and respiratory depression. When combined with furosemide, a loop diuretic that reduces blood volume and vascular resistance, there is a synergistic decrease in blood pressure, which may precipitate cardiovascular collapse, especially in patients with compromised circulatory reserves. Additionally, furosemide may enhance the sedative and respiratory depressant effects of alfentanil, leading to increased risk of respiratory acidosis and altered mental status."
"Alfentanil, a potent mu-opioid receptor agonist, can enhance the bradycardic effects of nebivolol, a beta-1 selective blocker with additional nitric oxide-mediated vasodilation. The combination may lead to excessive slowing of heart rate, reduced cardiac output, and potential hemodynamic instability, particularly in patients with underlying cardiac conduction abnormalities or hypovolemia."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about OXTELLAR XR vs ALFENTANIL, answered by our medical review team.
OXTELLAR XR is a Opioid Analgesic that works by Oxtellar XR (oxcarbazepine) is a prodrug that is converted to its active metabolite, MHD (10,11-dihydro-10-hydroxy-carbazepine). The exact mechanism of action is unknown, but it is thought to stabilize neuronal membranes by blocking voltage-gated sodium channels, thereby inhibiting repetitive neuronal firing and reducing the propagation of synaptic impulses.. ALFENTANIL is a Opioid Analgesic that works by Alfentanil is a potent, short-acting synthetic opioid analgesic that primarily acts as a mu-opioid receptor agonist. It binds to mu-opioid receptors in the central nervous system, leading to G-protein coupled activation of inwardly rectifying potassium channels and inhibition of voltage-gated calcium channels, resulting in hyperpolarization and reduced neurotransmitter release. This produces analgesia, sedation, and respiratory depression.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between OXTELLAR XR and ALFENTANIL depend on the specific clinical indication. These are both Opioid Analgesic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of OXTELLAR XR is: Oxcarbazepine extended-release (OXTELLAR XR) adult dosing: 600 mg orally twice daily; initial dose 300 mg twice daily, titrate by 300 mg/day increments weekly; maximum 2400 mg/day.. The standard adult dose of ALFENTANIL is: Initial IV bolus of 5-20 mcg/kg; maintenance infusion of 0.5-1.5 mcg/kg/min; incremental boluses of 5-10 mcg/kg as needed. Induction of anesthesia: 50-100 mcg/kg IV.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between OXTELLAR XR and ALFENTANIL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. OXTELLAR XR is classified as Category C. Oxcarbazepine, the active moiety in Oxtellar XR, is associated with an increased risk of major congenital malformations, particularly neural tube defects, craniofacial defects, and. ALFENTANIL is classified as Category C. Alfentanil is an opioid analgesic; limited human data. No clear evidence of major malformations, but third trimester use may cause neonatal opioid withdrawal syndrome (NOWS). Avoid. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.